Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of the IL4I1 Enzyme Expression in Patients With Cutaneous Melanoma
NCT04253080Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2022
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
Trial (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Role of IL4I1+ cells in prognosis and in response to treatments at 12 months. Started Apr 2022; status: completed.
Beyond the preview
Go deeper on NCT04253080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04253080.